Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa multicenter double-blind trial of low-dose oral diazoxide in relapsing-remitting multiple sclerosis
2010-023048-34Phase 2Active
- Sponsor
- Neurotech Pharmaceuticals
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Low-dose oral diazoxide with Placebo (2 arms). Primary endpoint: Cumulative number of new MRI lesions. Started Jan 2011; status: active.
02
Drugs
diazoxide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-023048-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023048-34.